1. Home
  2. INTS vs KPLT Comparison

INTS vs KPLT Comparison

Compare INTS & KPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INTS
  • KPLT
  • Stock Information
  • Founded
  • INTS 2012
  • KPLT 2012
  • Country
  • INTS United States
  • KPLT United States
  • Employees
  • INTS N/A
  • KPLT N/A
  • Industry
  • INTS Biotechnology: Pharmaceutical Preparations
  • KPLT Diversified Commercial Services
  • Sector
  • INTS Health Care
  • KPLT Consumer Discretionary
  • Exchange
  • INTS Nasdaq
  • KPLT Nasdaq
  • Market Cap
  • INTS 30.8M
  • KPLT 35.6M
  • IPO Year
  • INTS 2023
  • KPLT N/A
  • Fundamental
  • Price
  • INTS $0.54
  • KPLT $7.18
  • Analyst Decision
  • INTS Strong Buy
  • KPLT Hold
  • Analyst Count
  • INTS 3
  • KPLT 2
  • Target Price
  • INTS $8.50
  • KPLT $12.00
  • AVG Volume (30 Days)
  • INTS 362.2K
  • KPLT 19.2K
  • Earning Date
  • INTS 05-20-2025
  • KPLT 05-15-2025
  • Dividend Yield
  • INTS N/A
  • KPLT N/A
  • EPS Growth
  • INTS N/A
  • KPLT N/A
  • EPS
  • INTS N/A
  • KPLT N/A
  • Revenue
  • INTS N/A
  • KPLT $247,194,000.00
  • Revenue This Year
  • INTS N/A
  • KPLT $20.12
  • Revenue Next Year
  • INTS N/A
  • KPLT $13.19
  • P/E Ratio
  • INTS N/A
  • KPLT N/A
  • Revenue Growth
  • INTS N/A
  • KPLT 11.56
  • 52 Week Low
  • INTS $0.50
  • KPLT $5.08
  • 52 Week High
  • INTS $5.28
  • KPLT $23.54
  • Technical
  • Relative Strength Index (RSI)
  • INTS 18.34
  • KPLT 38.20
  • Support Level
  • INTS $0.55
  • KPLT $6.80
  • Resistance Level
  • INTS $0.59
  • KPLT $7.55
  • Average True Range (ATR)
  • INTS 0.12
  • KPLT 0.43
  • MACD
  • INTS -0.02
  • KPLT 0.12
  • Stochastic Oscillator
  • INTS 4.71
  • KPLT 32.86

About INTS Intensity Therapeutics Inc. Common stock

Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.

About KPLT Katapult Holdings Inc.

Katapult Holdings Inc. is a technology-driven lease-to-own platform that integrates with omni-channel retailers and e-commerce platforms to power the purchase of everyday durable goods for underserved U.S. non-prime consumers. It is an e-commerce-focused FinTech company offering a lease-purchase solution to consumers and enabling essential transactions at the merchant point of sale. Katapult is associated with hundreds of retailers across the United States.

Share on Social Networks: